Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience
Rowen RJ. Medical Gas Research, 2019.
- Study type
- Narrative review
- People studied
- No participants of its own (narrative review)
- Published
- 2019, Medical Gas Research
- Identifiers
- PMID 31898609, DOI 10.4103/2045-9912.273962
What the authors reported
A narrative review arguing ozone therapy could serve as an adjunctive or stand-alone treatment for drug-resistant infections and outbreaks such as Ebola, describing it as having a strong safety record.
What limits this result
A single author's advocacy-oriented narrative review with no systematic search or new controlled data, and no study of ozone against Borrelia or Lyme disease specifically.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Lyme Disease: What the Evidence Does and Doesn't Show
What CDC, the IDSA/AAN/ACR Lyme guideline, and a PubMed search for ozone and Borrelia actually show about EBO2 (also called EBOO) for Lyme disease.